表达产气荚膜梭菌类毒素α、β2、ε和β1的重组干酪乳杆菌对家兔产气荚膜梭菌感染的保护作用
本研究以干酪乳杆菌ATCC 393为抗原递送系统,表达产气荚膜梭菌类毒素α-β2-ε-β1,构建重组菌株pPG-2-α-β2-ε-β1/L. casei 393。家兔口服免疫后,疫苗组产生局部黏膜和全身免疫应答,脾淋巴细胞增殖,IL-4和IFN-γ水平显著高于对照组,CD4+和CD8+T细胞百分比显著升高;用1×LD100单位的C型或D型产气荚膜梭菌培养滤液攻击后,疫苗组家兔100%存活,对照组家兔48小时内死亡。
要点
- 口服重组干酪乳杆菌可同时激发家兔体液免疫和细胞免疫。
- 攻击后疫苗组家兔100%存活,对照组家兔48小时内死亡。
- 对照组家兔心、肝、脾、肺、肾、肠、脑可见明显组织病理学改变,疫苗组无明显改变。
核心结论
- pPG-2-α-β2-ε-β1/L. casei 393可引发有效的免疫保护,作者认为其可作为开发抗产气荚膜梭菌疫苗的候选。
研究设计与样本
- 以干酪乳杆菌ATCC 393为抗原递送系统构建表达产气荚膜梭菌类毒素α-β2-ε-β1的重组菌株,经1%木糖诱导后用Western-blotting鉴定特异性和完整性;以家兔为天然动物模型口服免疫,用ELISA测定特异性IgG和sIgA滴度,并检测脾淋巴细胞增殖、IL-4和IFN-γ水平及流式细胞术检测CD4+和CD8+T细胞百分比;随后用1×LD100单位的C型和D型产气荚膜梭菌培养滤液分别攻击疫苗组和对照组家兔,观察存活及组织病理学变化。
主要发现
- 口服重组菌可引发家兔局部黏膜和全身免疫应答。
- 疫苗组家兔脾淋巴细胞增殖,IL-4和IFN-γ水平显著高于对照组。
- 流式细胞术显示疫苗组CD4+T细胞和CD8+T细胞百分比均显著高于对照组。
- 用1×LD100单位C型和D型产气荚膜梭菌培养滤液攻击后,疫苗组家兔100%存活,对照组家兔48小时内死亡。
- 对照组家兔心、肝、脾、肺、肾、肠、脑可见明显组织病理学改变,疫苗组无明显改变。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The present study used Lactobacillus casei ATCC 393 as antigen delivery system to express C. perfringens toxoids α-β2-ε-β1 to construct the recombination Lactobacillus casei pPG-2-α-β2-ε-β1/L. casei 393. After being induced by 1% xylose, the specificity and integrity of recombinant strain were determined by Western-blotting. Rabbits as native animal model were immunized orally with pPG-2-α-β2-ε-β1/L. casei 393 and the titers of specific IgG and sIgA were determined by ELISA. The result showed that oral administration with the recombinants could elicit both local mucosal and systemic immune responses. The proliferation of spleen lymphocytes in rabbits immunized with pPG-2-α-β2-ε-β1/L. casei 393 was observed. Levels of IL-4 and IFN-γ produced were significantly higher in lymphocytes isolated from the vaccine group than those from the control groups. Flow cytometry assay showed that both the percentages of CD4+T cells and CD8+T cells from the vaccine group were significantly increased than the control groups. All these results showed that immunizing with recombinants can elicit both humoral immunity and cellular immunity. Besides, in order to determine the effectiveness of oral immunization with pPG-2-α-β2-ε-β1/L. casei 393, rabbits of vaccine group and control groups were challenged with 1×LD100 unit of culture filtrate of C. perfringens type C and type D toxins respectively. After challenge, 100% of the immunized rabbits survived, while the rabbits of the control group were killed within 48h. Observation on histopathology showed that histopathological changes were obviously found in heart, liver, spleen, lung, kidney, intestine and brain of rabbits from the control groups, while no apparent histopathological change was observed in the vaccine group. All the results show that pPG-2-α-β2-ε-β1/L. casei 393 can eliciteffective immunoprotection against C. perfringens. All of these suggest that the use of pPG-2-α-β2-ε-β1/L. casei 393 can be regarded as candidate for the development of a vaccine against C. perfringens.
引用
- Zhao L, Guo Z, Liu J, et al. Recombinant Lactobacillus casei expressing Clostridium perfringens toxoids α, β2, ε and β1 gives protection against Clostridium perfringens in rabbits. Vaccine. 2017. PMID: 28625525. doi:10.1016/j.vaccine.2017.05.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。